Glenmark Pharmaceuticals Ltd gets US FDA warning letter for Goa manufacturing facility

Glenmark Pharmaceuticals Limited had earlier announced about the Official Action Indicated (OAI) status of the Company's Goa (India) manufacturing facility by US FDA following the inspection conducted in May 2022. The US FDA has now issued a warning letter to the Goa (India) facility.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The Company is committed to work along with the US FDA to implement all the necessary corrective actions required to address the concerns at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 425.35 as compared to the previous close of Rs. 422.30. The total number of shares traded during the day was 27440 in over 1146 trades.

The stock hit an intraday high of Rs. 426.05 and intraday low of 417.40. The net turnover during the day was Rs. 11594013.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA WarningLetter GoaFacility